FUNDED BY
Ireland’s pharmaceutical sector has transformed over the past 50 years, from an API manufacturing base to a global hub for high value activities including process R&D, formulation, bioprocessing, and biotechnology. A major recent shift has been the adoption of continuous flow technology, offering improvements in safety, efficiency, and flexibility. While integrating flow into a highly regulated environment is complex, Ireland’s ecosystem, multinational API sites, CDMOs, and innovative indigenous companies, has successfully advanced large scale API and RSM manufacture through strong collaboration with regulatory agencies. This commentary highlights key factors enabling this transition and the current state of continuous flow in API/RSM production.
https://doi.org/10.1021/acs.oprd.5c00309
Partners: Eli Lilly, MSD, Pfizer, JnJ, sk biotek, apc, almac, WAB, arran chemical, UCC, UCD, UL.
Rinn Pharma & Biopharma, in partnership with leading research institutions across Ireland, is seeking motivated and talented PhD researchers to join a range of exciting research programmes. Research Themes Include: Cell-Expressed & RNA Therapeutics Advanced...
Dr Sarah Hayes, Chief Operations Officer at Rinn Pharma & Biopharma, has been named Biopharma & Lifesciences Connected Person of the Month for June 2026. Sarah has been selected in recognition of her outstanding leadership and contribution to Ireland’s...